NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Enterome

Enterome

Private
ParisHealthcare & Life Scienceshttps://www.enterome.com/

Last Round

VC Round

Jun 12, 2025

Total Funding Raised

$179.97M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Enterome is a biotechnology company that develops immunomodulatory drugs and therapeutic vaccines for cancer and immune-related diseases based on its proprietary gut microbiome-derived Mimicry platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

immunotherapymicrobiomedrug discoverygut microbiomecancer immunotherapybiotechclinical-stage biotechbacterial antigensai drug discoveryin silico drug designprecision medicinetherapeutic pipelinemicrobiome therapeuticssynthetic peptidespharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enterome Comparables

Compare Enterome with similar companies based on industry and business-model similarity.

Enterome comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Exeliom Biosciences
78%
MaaT Pharma
78%
Vedanta Biosciences
74%

Enterome Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJun 12, 2025
VC RoundJun 12, 2024
Early FundingAug 25, 2023
Series EJun 25, 2020
Series DJan 4, 2018
Debt
Jan 4, 2018

Key People

Founding team and executive leadership

Christelle Dumoussaud

Chief Financial Officer

Executive Team

Enterome Investors

Notable investors and investment history

Enterome investors
InvestorRounds
Lundbeck FoundationSeries D, Series B, Series A, Series C
NatixisVC Round, Series D, Series B, Series E, Series A
SymBiosis Capital ManagementSeries E, VC Round
Lundbeckfonden BioCapitalVC Round
INRAE TransfertSeed, Series C
European Investment Bank GroupDebt
Primo CapitalVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 29, 2026

    Mehrdad Mobasher, M.D., M.P.H. joins the Board of Directors.

  • Jun 12, 2025

    $19M round led by Institute for Follicular Lymphoma Innovation

Enterome Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Enterome Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Enterome's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range33
Year Founded2012
Last FundingJun 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.